Comparison of clinically nonpalpable prostate-specific antigen-detected (cT1c) versus palpable (cT2) prostate cancers in patients undergoing radical retropubic prostatectomy
- 1 July 1999
- Vol. 54 (1) , 105-110
- https://doi.org/10.1016/s0090-4295(99)00055-2
Abstract
No abstract availableKeywords
This publication has 25 references indexed in Scilit:
- Characteristics of Prostate Cancer Detected in the American Cancer Society-National Prostate Cancer Detection ProjectJournal of Urology, 1994
- The Nature of Prostate Cancer Detected Through Prostate Specific Antigen Based ScreeningJournal of Urology, 1994
- Comparison of Digital Rectal Examination and Serum Prostate Specific Antigen in the Early Detection of Prostate Cancer: Results of a Multicenter Clinical Trial of 6,630 MenJournal of Urology, 1994
- Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancerPublished by American Medical Association (AMA) ,1994
- PSA-DETECTED (CLINICAL STAGE T1c OR B0) PROSTATE CANCERUrologic Clinics of North America, 1993
- Biopsy proved prostate cancer in 100 consecutive men with benign digital rectal examination and elevated serum prostate-specific antigen level: Prevalence and pathologic characteristicsUrology, 1993
- Detection of organ-confined prostate cancer is increased through prostate-specific antigen-based screeningPublished by American Medical Association (AMA) ,1993
- Screening for Prostatic Carcinoma with Prostate Specific AntigenJournal of Urology, 1992
- Measurement of Prostate-Specific Antigen in Serum as a Screening Test for Prostate CancerNew England Journal of Medicine, 1991
- Prostate Cancer Detection in a Clinical Urological Practice by Ultrasonography, Digital Rectal Examination and Prostate Specific AntigenJournal of Urology, 1990